Cargando…
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
Several studies have suggested that estrogens have a protective function against lymphomagenesis. The treatment of breast cancer is driven by subtype classification, and the assessment of hormone receptor status is important for treatment selection. Thus, we evaluated the association between breast...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671407/ https://www.ncbi.nlm.nih.gov/pubmed/34907177 http://dx.doi.org/10.1038/s41408-021-00595-0 |
_version_ | 1784615128879071232 |
---|---|
author | Kang, Danbee Yoon, Sang Eun Shin, Dongwook Lee, Jin Hong, Yun Soo Lee, Se Kyung Lee, Jeong Eon Park, Yeon Hee Ahn, Jin Seok Guallar, Eliseo Kim, Won Seog Lee, Jungho Kim, Seok Jin Cho, Juhee |
author_facet | Kang, Danbee Yoon, Sang Eun Shin, Dongwook Lee, Jin Hong, Yun Soo Lee, Se Kyung Lee, Jeong Eon Park, Yeon Hee Ahn, Jin Seok Guallar, Eliseo Kim, Won Seog Lee, Jungho Kim, Seok Jin Cho, Juhee |
author_sort | Kang, Danbee |
collection | PubMed |
description | Several studies have suggested that estrogens have a protective function against lymphomagenesis. The treatment of breast cancer is driven by subtype classification, and the assessment of hormone receptor status is important for treatment selection. Thus, we evaluated the association between breast cancer and the incidence of NHL. We conducted a retrospective cohort study using a population-based nationwide registry in South Korea. We selected all women with newly diagnosed breast cancer between January 1st, 2002 and December 31st, 2016 who received curative treatment (N = 84,969) and a 1:10 sample of age-matched non-breast cancer controls (N = 1,057,674). Incident breast cancer (time-varying exposure) was the exposure and development of any type of NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mature T/NK-cell lymphomas, anaplastic large cell lymphoma (ALCL), and unspecified types of NHL, was the outcome. During follow-up, 1564 incident cases of NHL occurred. The fully adjusted Hazard Ratio (HR) for NHL associated with the development of breast cancer was 1.64 (95% CI = 1.34–2.00) after adjusting for body mass index, alcohol intake, physical activity, smoking, income, and comorbidity. The adjusted HR for NHL was much higher in participants who were aged <50 years and who received hormone therapy (either tamoxifen or aromatase inhibitors) than in those ≥50 years or who did not receive hormone therapy, respectively. The development of breast cancer was associated with a significantly increased risk of NHL, particularly follicular lymphoma and mature T/NK-cell lymphoma. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients. |
format | Online Article Text |
id | pubmed-8671407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86714072021-12-28 Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study Kang, Danbee Yoon, Sang Eun Shin, Dongwook Lee, Jin Hong, Yun Soo Lee, Se Kyung Lee, Jeong Eon Park, Yeon Hee Ahn, Jin Seok Guallar, Eliseo Kim, Won Seog Lee, Jungho Kim, Seok Jin Cho, Juhee Blood Cancer J Article Several studies have suggested that estrogens have a protective function against lymphomagenesis. The treatment of breast cancer is driven by subtype classification, and the assessment of hormone receptor status is important for treatment selection. Thus, we evaluated the association between breast cancer and the incidence of NHL. We conducted a retrospective cohort study using a population-based nationwide registry in South Korea. We selected all women with newly diagnosed breast cancer between January 1st, 2002 and December 31st, 2016 who received curative treatment (N = 84,969) and a 1:10 sample of age-matched non-breast cancer controls (N = 1,057,674). Incident breast cancer (time-varying exposure) was the exposure and development of any type of NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mature T/NK-cell lymphomas, anaplastic large cell lymphoma (ALCL), and unspecified types of NHL, was the outcome. During follow-up, 1564 incident cases of NHL occurred. The fully adjusted Hazard Ratio (HR) for NHL associated with the development of breast cancer was 1.64 (95% CI = 1.34–2.00) after adjusting for body mass index, alcohol intake, physical activity, smoking, income, and comorbidity. The adjusted HR for NHL was much higher in participants who were aged <50 years and who received hormone therapy (either tamoxifen or aromatase inhibitors) than in those ≥50 years or who did not receive hormone therapy, respectively. The development of breast cancer was associated with a significantly increased risk of NHL, particularly follicular lymphoma and mature T/NK-cell lymphoma. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients. Nature Publishing Group UK 2021-12-14 /pmc/articles/PMC8671407/ /pubmed/34907177 http://dx.doi.org/10.1038/s41408-021-00595-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kang, Danbee Yoon, Sang Eun Shin, Dongwook Lee, Jin Hong, Yun Soo Lee, Se Kyung Lee, Jeong Eon Park, Yeon Hee Ahn, Jin Seok Guallar, Eliseo Kim, Won Seog Lee, Jungho Kim, Seok Jin Cho, Juhee Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title_full | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title_fullStr | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title_full_unstemmed | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title_short | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
title_sort | risk of non-hodgkin lymphoma in breast cancer survivors: a nationwide cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671407/ https://www.ncbi.nlm.nih.gov/pubmed/34907177 http://dx.doi.org/10.1038/s41408-021-00595-0 |
work_keys_str_mv | AT kangdanbee riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT yoonsangeun riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT shindongwook riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT leejin riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT hongyunsoo riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT leesekyung riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT leejeongeon riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT parkyeonhee riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT ahnjinseok riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT guallareliseo riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT kimwonseog riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT leejungho riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT kimseokjin riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy AT chojuhee riskofnonhodgkinlymphomainbreastcancersurvivorsanationwidecohortstudy |